UBS Starts Caris Life Sciences Inc (CAI) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CAI Hot Sheet
Price: $33.22 +1.13%
Rating Summary:
12 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
12 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
UBS analyst Douglas Schenkel initiates coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Neutral rating and a price target of $28.00.
For an analyst ratings summary and ratings history on Caris Life Sciences Inc click here. For more ratings news on Caris Life Sciences Inc click here.
Shares of Caris Life Sciences Inc closed at $24.82 yesterday.
You May Also Be Interested In
- CAI International (CAI) Misses Q3 EPS by 11c ; Offers Guidance
- Morgan Stanley Starts Elevate Campuses Ltd (ELEVATE:IN) at Overweight
- Bernstein SocGen Group Starts Abbott India Ltd (BOOT:IN) at Market Perform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
